Table 2.
Viral and HBsAg responses during treatment
| Variables | All patients (n = 150) | HBeAg-positive patients (n = 83) | HBeAg-negative patients (n = 67) | t | P |
|---|---|---|---|---|---|
| Time to viral response (weeks) | 3.081 | 0.003 | |||
| Mean ± SD | 21.7 ± 13.4 | 24.8 ± 15.1 | 17.2 ± 9.0 | ||
| Median (Q1–Q3) | 15.0 (11.0–26.0) | 18.5 (11.0–37.0) | 14.0 (11.0–20.0) | ||
| HBsAg decrease at 12 weeks (log IU/ml) | 0.899 | 0.370 | |||
| Mean ± SD | 1.6 ± 1.5 | 1.7 ± 1.6 | 1.5 ± 1.3 | ||
| Median (Q1–Q3) | 1.1 (0.2–2.7) | 1.3 (0.2–2.7) | 1.0 (0.3–2.7) | ||
| Percentage of HBsAg decline at 12 weeks (%), median (Q1–Q3) | 48.3 (47.2–99.7) | 40.7 (34.0–99.4) | 56.3 (47.2–99.7) | 1.379 | 0.171 |
| HBsAg decline at 24 weeks (log IU/ml) | 0.286 | 0.775 | |||
| Mean ± SD | 2.3 ± 1.4 | 2.3 ± 1.6 | 2.3 ± 1.2 | ||
| Median (Q1–Q3) | 2.2 (1.1–3.4) | 1.9 (0.9–3.6) | 2.3 (1.2–3.3) | ||
| Percentage of HBsAg decline at 24 weeks (%), median (Q1–Q3) | 88.3 (60.9–100.0) | 85.9 (53.5–100.0) | 92.3 (70.4–100.0) | 0.066 | 0.948 |
| Time HBsAg loss (weeks) | 2.905 | 0.004 | |||
| Mean ± SD | 54.2 ± 30.3 | 60.6 ± 29.8 | 46.5 ± 29.3 | ||
| Median (Q1–Q3) | 53.0 (25.0–80.0) | 62.0 (38.0–85.0) | 41.0 (21.0–71.0) | ||
| Patients with seroconversion, n (%) | 117 (78.0) | 67 (80.7) | 50 (74.6) | 0.430* | |
| Time to HBsAg seroconversion (weeks) | 2.420 | 0.017 | |||
| Mean ± SD | 56.5 ± 28.5 | 61.9 ± 28.2 | 49.3 ± 27.5 | ||
| Median (Q1–Q3) | 55.5 (28.0–77.0) | 62.5 (39.0–85.0) | 49.5 (24.0–70.0) |
*Fisher’s exact test. SD: Standard deviation; HBsAg: Hepatitis B surface antigen.